Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir versus placebo for proven fetal congenital cytomegalovirus infection
2007-005525-29Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in congenital cytomegalovirus infection (cCMV) comparing Valaciclovir with Placebo (2 arms). Primary endpoints: Effect of maternal oral valaciclovir on unfavorable fetal and neonatal outcomes and Reduction in unfavorable outcomes. Started Jun 2009; status: active.
02
Drugs
valaciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on 2007-005525-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005525-29.